Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Li-Ta Keng
Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma
Oncotarget
Oncology
Paradoxical Response With Miliary Pulmonary Nodules in a Patient With Tuberculous Pericarditis
CMAJ
Medicine
Related publications
P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States
Journal of Medical Economics
Health Policy
The Profile of Lung Adenocarcinoma Patients With Positive EGFR Mutation
Green Medical Journal
Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC
Neoplasma
Cancer Research
P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
